

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1501	((546/335) or (546/269.7)).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/09/24 23:42
L2	105	1 and pioglitazone	US-PGPUB; USPAT	OR	OFF	2007/09/24 23:42
L3	77	1 and pioglitazone and intermediate	US-PGPUB; USPAT	OR	OFF	2007/09/24 23:42

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS	6	JUL 16	CAPLUS enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPLUS patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	BEILSTEIN updated with new compounds
NEWS	12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	13	AUG 13	CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS	14	AUG 20	CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS	15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	16	AUG 27	USPATOLD now available on STN
NEWS	17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	19	SEP 13	FORIS renamed to SOFIS
NEWS	20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	21	SEP 17	CA/CAPLUS enhanced with printed CA page images from 1967-1998
NEWS	22	SEP 17	CAPLUS coverage extended to include traditional medicine patents
NEWS	23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS EXPRESS	19	SEPTEMBER 2007	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

Updated Search

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1  
DICTIONARY FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\awer.str

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 22:03:20 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4311 TO ITERATE

46.4% PROCESSED 2000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 82283 TO 90157  
PROJECTED ANSWERS: 2 TO 210

L2 2 SEA SSS SAM L1

=> s l1 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 22:03:23 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 86500 TO ITERATE

Updated Search

100.0% PROCESSED 86500 ITERATIONS  
SEARCH TIME: 00.00.01

35 ANSWERS

L3 35 SEA SSS FUL L1

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
175.25	175.46

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2007 VOL 147 ISS 14  
FILE LAST UPDATED: 23 Sep 2007 (20070923/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 17 L3

=> s 14 and chupak, l?/au

17 CHUPAK, L?/AU

L5 0 L4 AND CHUPAK, L?/AU

=> s 14 and boyer, f?/au

168 BOYER, F?/AU

L6 0 L4 AND BOYER, F?/AU

=> s 14 and hagen, s?/au

363 HAGEN, S?/AU

L7 0 L4 AND HAGEN, S?/AU

=> s 14 and kaneko, t?/au

6847 KANEKO, T?/AU

L8 0 L4 AND KANEKO, T?/AU

=> s 14 and lall, m?/au

17 LALL, M?/AU

L9 0 L4 AND LALL, M?/AU

=> s 4 and pettersson, m?/au

5677402 4

168 PETTERSSON, M?/AU

Updated Search

L10 32 4 AND PETTERSSON, M?/AU

=> s 14 and lall, m?/au  
17 LALL, M?/AU

L11 0 L4 AND LALL, M?/AU

=> s 14 and pettersson, m?/au  
168 PETTERSSON, M?/AU

L12 0 L4 AND PETTERSSON, M?/AU

=> s 14 and prasad, j?/au  
808 PRASAD, J?/AU

L13 0 L4 AND PRASAD, J?/AU

=> d 14, ibib abs hitstr, 1-17

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:183978 HCAPLUS

DOCUMENT NUMBER: 146:417429

TITLE: Synthesis and Binding Affinity of a  
Fluorine-Substituted Peroxisome Proliferator-Activated  
Gamma (PPAR $\gamma$ ) Ligand as a Potential Positron  
Emission Tomography (PET) Imaging Agent

AUTHOR(S): Lee, Byung Chul; Lee, Kyo Chul; Lee, Hsiaoju; Mach,  
Robert H.; Katzenellenbogen, John A.

CORPORATE SOURCE: Department of Chemistry, University of Illinois,  
Urbana, IL, 61801, USA

SOURCE: Bioconjugate Chemistry (2007), 18(2), 507-513  
CODEN: BCCHE; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) is an important regulator of lipid metabolism and the differentiation of pre-adipocytes. Thus, imaging PPAR $\gamma$  in vivo using positron-emission tomog. (PET) might be useful in assessing lipid metabolism disorders and identifying tumor cell differentiation. A fluorine-substituted PPAR $\gamma$  ligand from tyrosine-benzophenone class, compound 1, has a very high affinity for PPAR $\gamma$  receptor ( $K_i = 0.14$  nM). To develop this compound as a PPAR $\gamma$  PET imaging agent, we investigated synthetic routes suitable for its labeling with the short-lived PET radionuclide fluorine-18 ( $t_{1/2} = 110$  min). To obtain the high specific activity material needed for receptor imaging with this isotope, reactions need to proceed efficiently, within a short time, starting from fluoride ion at the tracer level. The most promising approach involves introduction of fluorine into a suitable benzophenone precursor, followed by efficient coupling of this intermediate with the heterocyclic tyrosine component using a copper-catalyzed Ullmann-type condensation.

IT 258347-27-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and binding affinity of fluorine-substituted PPAR $\gamma$  ligand as potential PET imaging agent)

RN 258347-27-2 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 185679-35-0

CMF C21 H22 N2 O4

Updated Search


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1342501 HCAPLUS

DOCUMENT NUMBER: 145:397748

TITLE: Improved synthesis of a new antidiabetic agent, GW409544

AUTHOR(S): Zhou, Xinbo; Lin, Cuifang; Li, Song

CORPORATE SOURCE: School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning Province, 110016, Peop. Rep. China

SOURCE: Zhongguo Yaowu Huaxue Zazhi (2005), 15(3), 167-169  
CODEN: ZYHZEJ; ISSN: 1005-0108

PUBLISHER: Zhongguo Yaowu Huaxue Zazhi Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

OTHER SOURCE(S): CASREACT 145:397748

AB The synthesis of GW409544 was reported. GW409544 was synthesized by using Me 3-oxopentanoate and L-tyrosine as the starting material via nine steps, such as esterification, amino protection, bromination, cyclization, reduction, etherification, deprotection, hydrolysis, condensation and salt formation, etc. The target compound was identified by spectroscopic anal., and the overall yield was 9.3%. The preparative method of Me 2-(5-methyl-2-phenyl-4-oxazolyl)acetate and (S)-Me 2-(tert-butoxycarbonylamino)-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propanoate [or, i.e., N-[(1,1-dimethylethoxy)carbonyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-L-tyrosine Me ester] were improved.

IT 185679-35-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of GW-409544 using O-[2-[methyl(phenyl)oxazolyl]ethyl]-L-tyrosine as reactant)

RN 185679-35-0 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)



Updated Search

Absolute stereochemistry.



L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:1016040 HCAPLUS  
DOCUMENT NUMBER: 141:424180  
TITLE: Processes for making thiazolidinedione derivatives and compounds thereof  
INVENTOR(S): Pospisilik, Karel; Zhu, Jie; Picha, Frantisek  
PATENT ASSIGNEE(S): Synthon B.V., Neth.  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101560	A1	20041125	WO 2004-EP5026	20040511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005059708	A1	20050317	US 2004-842635	20040511
EP 1622898	A1	20060208	EP 2004-732115	20040511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812988	A	20060802	CN 2004-80018359	20040511
JP 2007502847	T	20070215	JP 2006-529780	20040511
PRIORITY APPLN. INFO.:			US 2003-469837P	P 20030513
			WO 2004-EP5026	W 20040511
OTHER SOURCE(S):		MARPAT 141:424180		
GI				



Updated Search




AB The invention relates processes for the synthesis of thiazolidinedione derivs. I (A is ethyl-2-pyridylethyl, [(2-pyridyl)methylamino]ethyl or [3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methyl] via reactions of amino acid intermediates II (same A, R is H or alkyl, Q is H or an amine-protecting group). The synthesis of pioglitazone is illustrated. Thus, 2-amino-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]propionic acid, prepared by O-alkylation of L-tyrosine, underwent diazotization reaction to give the 2-bromo derivative which underwent cyclocondensation with thiourea to afford pioglitazone (isolated as the HCl salt).

IT 794591-56-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Processes for making thiazolidinedione derivs. and compds. thereof)

RN 794591-56-3 HCAPLUS

CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:996131 HCAPLUS

DOCUMENT NUMBER: 141:424428

TITLE: Intermediate compound, namely O-[2-(5-ethylpyridin-2-yl)ethyl]tyrosine, which is used for the preparation of the antidiabetic agent pioglitazone, and methods for its preparation and conversion to pioglitazone

INVENTOR(S): Duran, Lopez Ernesto

PATENT ASSIGNEE(S): Medichem, S.A., Spain

SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish





FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099147	A1	20041118	WO 2004-ES70031	20040504
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2219180	A1	20041116	ES 2003-1075	20030509



ES 2219180	B1	20060301		
CA 2525190	A1	20041118	CA 2004-2525190	20040504
EP 1623977	A1	20060208	EP 2004-731028	20040504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007083050	A1	20070412	US 2006-555659	20061219
PRIORITY APPLN. INFO.:			ES 2003-1075	A 20030509
			WO 2004-ES70031	W 20040504
OTHER SOURCE(S): CASREACT 141:424428; MARPAT 141:424428				
GI				



AB The invention relates to the novel O-substituted tyrosine derivative I, including pure or mixed enantiomers, racemates, salts, solvates, and hydrates. I and its stereoisomers and compds. are new key intermediates for the preparation of the antidiabetic agent pioglitazone (II). The invention also relates to a method of obtaining I from a natural product, L-tyrosine, in which the amino group, in the form of an aromatic imine group, is protected by an aldehyde or ketone. The invention further relates to a method of obtaining II from the intermediate compound I. The critical feature of the invention is protection of the tyrosine N-terminal as an imine, which allows etherification of the phenolic tyrosine OH group to occur without competing N-alkylation. Complete racemization during the process allows the more desirable racemic I to be prepared from the more readily available L-tyrosine. For instance, L-tyrosine was treated with SOCl<sub>2</sub> in refluxing MeOH to give the Me ester, which was treated with PhCHO at room temperature in CH<sub>2</sub>Cl<sub>2</sub> to give doubly protected tyrosine III. This phenolic compound was etherified with the mesylate IV (preparation given) using K<sub>2</sub>CO<sub>3</sub> and

Bu<sub>4</sub>N<sup>+</sup>Br<sup>-</sup> in PhMe at 70°, and the protected product was deprotected in situ first with acid (2N HCl) and then with base (50% NaOH), both at

70°, to give racemic I in 62.8% overall yield from L-tyrosine. Diazotization of the amino group in I in the presence of HBr gave the corresponding bromo compound, which was cyclized with thiourea to give the 2-imine derivative of II. Acid hydrolysis of the imine in refluxing aqueous

HCl


gave II in 40.7% yield from I. Four comparative processes for preparing I, using other standard amine protecting groups instead of a benzaldehyde imine, were examined. Overall yields of I from L-tyrosine were 24.1% for Boc, 20.7% for Cbz, 11.5% for Ac, and poor (unisolated) for EtOCO, vs. 62.8% for benzylidene.

IT 795316-22-2P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-DL-tyrosine  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(target intermediate; intermediate compound which is used for the preparation

of pioglitazone)

RN 795316-22-2 HCAPLUS

CN Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




IT 794591-56-3P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-L-tyrosine  
795316-27-7P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-D-tyrosine  
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
(target intermediate; intermediate compound which is used for the preparation

of pioglitazone)

RN 794591-56-3 HCAPLUS

CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 795316-27-7 HCAPLUS

CN D-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

Updated Search

ACCESSION NUMBER: 2004:459234 HCAPLUS  
DOCUMENT NUMBER: 141:153305  
TITLE: Site-Specific Insertion of Spin-Labeled L-Amino Acids  
in Xenopus Oocytes  
AUTHOR(S): Shafer, Aaron M.; Kalai, Tamas; Liu, Sarah Qiao Bin;  
Hideg, Kalman; Voss, John C.  
CORPORATE SOURCE: Department of Biological Chemistry, University of  
California, Davis, CA, 95616, USA  
SOURCE: Biochemistry (2004), 43(26), 8470-8482  
CODEN: BICHAW; ISSN: 0006-2960  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:153305


AB Site-specific insertion of modified amino acids in proteins expressed in living cells is an emerging field holding great promise for elucidating protein structure-function relationships, expression levels, localization, and activation states in a complex milieu. To evaluate the efficiency of amino acids modified to carry either a nitroxide spin probe or a fluorescence probe, we have developed a screen using the levels of functional luciferase protein expressed in Xenopus oocytes. Natural and modified amino acids were targeted to position 14 in firefly luciferase using an amber mutation or introducing the four-codon nucleotide GGGU. Using the amber stop codon, the incorporation efficiencies of injected tRNA charged with the native phenylalanine residue, a fluorescent NBD-alanine, or nitroxide-labeled cysteine and tyrosine amino acids ranged from 1% to 18%. While the NBD-amino acid derivative gave higher incorporation levels, the EPR signals from the spin-labeled amino acids allow for the direct assessment of aminoacylation extent and stability. Applying the four-base codon for the first time in Xenopus oocytes, we found the incorporation efficiencies were significantly lowered compared to results using the three-base amber codon. The studies presented here provide quant. assessment of protein expression levels when using nonsense suppression to site-specifically label proteins with spectroscopic probes in oocytes. Finally, the effect of a 77-base RNA aptamer known to inhibit the eucaryotic release factor of protein synthesis was tested for its influence on nonsense incorporation in Xenopus oocytes. The combination of A34 and charged suppressor tRNA produced a 3-fold increase in the expressed TAG14-luciferase level, compared to the use of charged suppressor tRNA alone.

IT 729580-43-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(site-specific insertion of spin-labeled L-amino acids in Xenopus oocytes)

RN 729580-43-2 HCAPLUS

CN 1H-Pyrrol-1-yloxy, 3-[[4-[(2S)-2-amino-2-carboxyethyl]phenoxy]methyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:633643 HCAPLUS  
 DOCUMENT NUMBER: 139:180343  
 TITLE: Preparation of aromatic amino acid derivatives as anticancer agents  
 INVENTOR(S): Endo, Hitoshi; Kanai, Yoshikatsu; Tsujihara, Kenji; Saito, Kunio  
 PATENT ASSIGNEE(S): Japan  
 SOURCE: PCT Int. Appl., 124 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066574	A1	20030814	WO 2003-JP1081	20030203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475434	A1	20030814	CA 2003-2475434	20030203
AU 2003208105	A1	20030902	AU 2003-208105	20030203
EP 1481965	A1	20041201	EP 2003-703151	20030203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005119256	A1	20050602	US 2003-503125	20030203
CN 1630632	A	20050622	CN 2003-803549	20030203
PRIORITY APPLN. INFO.:			JP 2002-31216	A 20020207
			WO 2003-JP1081	W 20030203
OTHER SOURCE(S):			MARPAT 139:180343	
GI				



I

AB Aromatic amino acid derivs. represented by the following general formula (I) or pharmacol. acceptable salts thereof [wherein R1 represents hydrogen or an amino-protecting group; R2 represents hydrogen, alkylaralkyl or aryl; R3 represents (1) halogeno, (2) aroylamino, (3) Ph substituted by lower alkyl, Ph, phenoxy, etc., (4) naphthyl or tetrahydronaphthyl optionally substituted by hydroxy, lower alkoxy or di(lower alkyl)amino, (5) an N-, O- and/or S-containing unsatd. monocyclic heterocycle group substituted by lower alkyl, Ph, naphthyl or tetrahydroquinolyl, or (6) an N-, O- and/or S-containing fused heterocycle group, which may be unsatd. or partly saturated, optionally substituted by oxo, carboxy, amino, lower alkyl, etc.; X represents halogeno, alkyl or alkoxy; Y represents oxygen or nitrogen; p is 0 or 1; m is 0, 1 or 2; and n is an integer of from 0 to 5] are prepared. These compds. inhibit a transporter (LAT1) of essential amino acids which are one of the main nutrients for cancer cells and induce depletion of the essential amino acids in the cancer cells, thereby inhibit the proliferation of the cancer cells. Thus, 0.2 mL pyridine was added to a suspension of N-trifluoroacetyl-3-hydroxy-L-phenylalanine Et ester 159, 2-naphthaleneboronic acid 186, mol. sieve 4A 204, and Cu(OAc)2 153 mg in 7 mL CH2Cl2, stirred at room temperature for 16 h in air to give, after workup

and

silica gel chromatog., 89% N-trifluoroacetyl-3-(2-naphthyloxy)-L-phenylalanine Et ester (II). 0.5 N aqueous NaOH was added to a solution of II (94 mg) in 2 mL THF at 5°, stirred at 5° for 69 h, acidified with 1 N aqueous HCl to pH 3-4, and filtered to give 78% 3-(2-naphthyloxy)-L-phenylalanine (III). In an assay for a LAT1 inhibitory activity, III and 3-[3-(6-dimethylaminopyridyl)phenoxy]-L-phenylalanine in vitro showed IC50 of 0.1 and 0.01 µg/mL, resp., for inhibiting the uptake of [14C]-L-tyrosine by human prostatic cancer T24 cells.

IT 579524-29-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting

proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))

RN 579524-29-1 HCAPLUS

CN L-Tyrosine, 3,5-dichloro-O-[(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 579524-04-2P 579524-25-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of aromatic amino acid derivs. as anticancer agents for inhibiting

proliferation of cancer cells by inhibiting essential amino acid transporter (LAT1))

RN 579524-04-2 HCAPLUS

CN L-Tyrosine, 3,5-dichloro-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579524-25-7 HCAPLUS

CN L-Tyrosine, 3,5-dichloro-O-[[2-(4-methoxyphenyl)-5-methyl-7-benzoxazolyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:888693 HCAPLUS  
 DOCUMENT NUMBER: 137:385108  
 TITLE: Preparation of 2-amino-3-[3,5-dibromo-4-(3-bromobenzyloxy)phenyl]propionic acid and related compounds as thyroid hormone receptor antagonists for cardiac and metabolic disorders  
 INVENTOR(S): Malm, Johan; Brandt, Peter; Edvinsson, Karin; Ericsson, Thomas; Gordon, Sandra  
 PATENT ASSIGNEE(S): Karo Bio AB, Swed.  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092550	A1	20021121	WO 2002-EP4193	20020415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2446747	A1	20021121	CA 2002-2446747	20020415
AU 2002310850	A1	20021125	AU 2002-310850	20020415
EP 1387825	A1	20040211	EP 2002-735262	20020415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1509267	A	20040630	CN 2002-809941	20020415
JP 2004533450	T	20041104	JP 2002-589436	20020415
US 2004220147	A1	20041104	US 2004-477676	20040610



PRIORITY APPLN. INFO.:

GB 2001-11861  
WO 2002-EP4193

A 20010515  
W 20020415

OTHER SOURCE(S): MARPAT 137:385108


AB Compds. 3,5,4-R<sub>2</sub>,R<sub>3</sub>(R<sub>1</sub>CH<sub>2</sub>O)C<sub>6</sub>H<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>CHR<sub>4</sub>R<sub>5</sub> [I; R<sub>1</sub> = (un)substituted (hetero)aryl or cycloalkyl; R<sub>2</sub>, R<sub>3</sub> = Cl, Br, (cyclo)alkyl, alkenyl, alkynyl; R<sub>4</sub> = halo, OH, SH, NH<sub>2</sub>, alkylamino; R<sub>5</sub> = CO<sub>2</sub>H, PO<sub>3</sub>H<sub>2</sub>, P(O)(OH)NH<sub>2</sub>, SO<sub>3</sub>H, COCO<sub>2</sub>H, CONHOH; n = 1 or 2], including all possible stereoisomers, prodrug esters, and radioactive forms, were prepared as thyroid receptor ligands, preferably antagonists, for the treatment of cardiac arrhythmias, thyrotoxicosis, subclin. hyperthyroidism, and liver diseases. Thus, the title acid was prepared from Boc-Tyr-OMe (Boc = tert-butoxycarbonyl) by bromination, etherification with 3-bromobenzyl bromide, and deprotection using TFA. I exhibited binding affinities to the thyroid hormone receptor  $\alpha$  (ThRa) in the range of 100 nM to 10,000 nM. Compds. I exhibited binding affinities to the ThRa receptor in the range of 10 nM to 10,000 nM.

IT 475999-32-7P 475999-41-8P

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino[(benzyloxy)phenyl]propionic acid derivs. and related compds. as thyroid hormone receptor antagonists for cardiac and metabolic disorders)

RN 475999-32-7 HCAPLUS

CN Tyrosine, 3,5-dibromo-O-[(5-methyl-3-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 475999-41-8 HCAPLUS

CN Tyrosine, 3,5-dibromo-O-[(2-methyl-4-thiazolyl)methyl]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 475999-40-7

CMF C14 H14 Br2 N2 O3 S




CM 2

CRN 121-44-8

CMF C6 H15 N

Updated Search




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:516372 HCAPLUS  
 DOCUMENT NUMBER: 137:78955  
 TITLE: Preparation of benzimidazole- $\alpha$ -substituted carboxylic acid derivatives for prevention and/or treatment of diseases such as diabetes  
 INVENTOR(S): Fujita, Takashi; Wada, Kunio; Oguchi, Minoru; Honma, Hidehito; Fujiwara, Toshihiko; Iwabuchi, Haruo  
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 93 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002193948	A	20020710	JP 2001-308762	20011004
PRIORITY APPLN. INFO.:			JP 2000-307158	A 20001006
OTHER SOURCE(S):	MARPAT	137:78955		

GI



AB Disclosed are insulin-resistance improving agents, blood sugar-lowering agents, immune regulating agents, aldose reductase-inhibitors, 5-lipoxygenase-inhibitors, lipid peroxide formation-suppressing agents, peroxisome proliferator-activated receptor (PPAR)-activating agents leukotriene antagonists, fat cell-formation promoters, and calcium antagonists containing the title compds. [I; R1, R2, R3 = H, C1-6 alkyl, (un)substituted C6-10 aryl, (un)substituted C7-16, C1-6 alkylsulfonyl, C1-6 haloalkylsulfonyl, (un)substituted C6-10 arylsulfonyl, C7-16 aralkylsulfonyl; A = N, CH; B = O, S; W1 = C1-6 alkylene; W2 = single bond, C1-8 alkylene; X = H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, halo, HO, cyano, NO2, C3-10 cycloalkyl, (un)substituted C6-10 aryl, (un)substituted C7-16 aralkyl, C1-7 aliphatic acyl, C4-11 cycloalkylcarbonyl, (un)substituted C7-11 arylcarbonyl, C8-17 aralkylcarbonyl, (un)substituted monocyclic heterocyclylcarbonyl, CONH2, (un)substituted C7-11 arylaminocarbonyl, (un)substituted NH2; Y = O, S(O)p (p = 0-2); Z2 = (un)substituted saturated heterocyclyl or C6-10 aryl] or pharmacol. acceptable

salts as the active ingredients. They are useful for the prevention and/or treatment of diabetes, impaired glucose tolerance, neurosis, cataract, coronary artery disease, and gestational diabetes. Thus, a solution of 3-[4-[[[4-[4-(adamantan-1-yl)phenoxy]-2-(N-tert-butoxycarbonyl-N-methylamino)phenyl]amino]carbonyl]methoxy]phenyl]-2-(4-fluorobenzoyloxy)propionic acid Me ester in 4 N HCl/dioxane was stirred at room temperature for 1 h to give

3-[4-[6-[4-(adamantan-1-yl)phenoxy]-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]-2-(4-fluorobenzoyloxy)propanoic acid Me ester which was stirred with a mixture of 2 N aqueous NaOH and methanol at room temperature for 2 h; treated with THF, stirred for 4 h, poured into water, and neutralized with HCl and aqueous NaHCO<sub>3</sub> to give 3-[4-[[6-[4-(adamantan-1-yl)phenoxy]-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]-2-(4-fluorobenzoyloxy)propanoic acid (II). When a feed containing 0.01% II was fed to diabetic KK mice for 3 days, blood sugar level was lowered by 58.5%. A capsule, a tablet, and a granule formulation containing II were prepared


IT 440355-09-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazole- $\alpha$ -substituted carboxylic acid derivs. for prevention and/or treatment of diseases such as diabetes and impaired glucose tolerance)

RN 440355-09-9 HCAPLUS

CN Tyrosine, O-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L4 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:629484 HCAPLUS

DOCUMENT NUMBER: 136:6304

TITLE: The synthesis of GW710936X to support the development of potent PPAR $\gamma$  agonists

AUTHOR(S): Reynolds, D. J.; Hermitage, S. A.

CORPORATE SOURCE: Chemical Development Division, Medicines Research Centre, GlaxoSmithKline Research and Development, Hertfordshire, SG1 2NY, UK

SOURCE: Tetrahedron (2001), 57(36), 7765-7770  
CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 136:6304

AB (2S)-[(2-benzoyl-4-hydroxyphenyl)amino]-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propanoic acid (GW710936X) has been synthesized from

N-Cbz-L-tyrosine Me ester utilizing a copper(I)-catalyzed N-arylation as the key coupling step. The synthetic route was designed to be convergent and to facilitate ease of isolation of the unstable product that had proven to be unobtainable by concentration of exts. from biol. assays.

IT 185679-35-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of GW710936X to support the development of potent PPAR $\gamma$  agonists)  
 RN 185679-35-0 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:581856 HCAPLUS  
 DOCUMENT NUMBER: 135:152795  
 TITLE: Process for synthesis of oxazolethoxyphenylpropanoic acid derivative for use as NIDDM medicament  
 INVENTOR(S): Davis, Roman; Kennedy, Andrew  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057001	A1	20010809	WO 2001-EP1041	20010201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2000-2667 A 20000204  
 AB Process for synthesis of calcium salt of (2S)-2-[[[(2Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]amino]-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid and physiol. acceptable solvates thereof, useful as NIDDM medicament is disclosed.  
 IT 353239-35-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of oxazolethoxyphenylpropanoic acid derivative for NIDDM

Updated Search

medicament)  
 RN 353239-35-7 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, monohydrochloride  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:725618 HCAPLUS  
 DOCUMENT NUMBER: 133:281783  
 TITLE: Preparation of benzimidazolylalkoxyphenylalkanoic acid derivatives for the treatment of diabetes and other diseases  
 INVENTOR(S): Fujita, Takashi; Wada, Kunio; Oguchi, Minoru; Honma, Hidehito; Fujiwara, Toshihiko; Iwabuchi, Haruo  
 PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan  
 SOURCE: PCT Int. Appl., 235 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059889	A1	20001012	WO 2000-JP2215	20000406
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2369871	A1	20001012	CA 2000-2369871	20000406
JP 2001097955	A	20010410	JP 2000-104701	20000406
EP 1167357	A1	20020102	EP 2000-915361	20000406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 200102908	T2	20020422	TR 2001-2908	20000406
BR 2000009593	A	20020618	BR 2000-9593	20000406
HU 200200895	A2	20021128	HU 2002-895	20000406
AU 760163	B2	20030508	AU 2000-36707	20000406
NZ 514661	A	20030630	NZ 2000-514661	20000406
RU 2219172	C2	20031220	RU 2001-127083	20000406
IN 2001KN01023	A	20050311	IN 2001-KN1023	20011001
ZA 2001008168	A	20030218	ZA 2001-8168	20011004
NO 2001004849	A	20011127	NO 2001-4849	20011005
MX 2001PA10109	A	20020604	MX 2001-PA10109	20011005
US 2003069294	A1	20030410	US 2001-972206	20011005

Updated Search

US 6596751	B2	20030722		
US 2004002512	A1	20040101	US 2003-376942	20030228
PRIORITY APPLN. INFO.:			JP 1999-99286	A 19990406
			JP 1999-215141	A 19990729
			WO 2000-JP2215	W 20000406
			US 2001-972206	A3 20011005

OTHER SOURCE(S): MARPAT 133:281783  
GI



AB The title compds. I [R1 is alkyl or the like; R2 is hydrogen or the like; R3 is hydrogen or the like; A is CH or the like; B is oxygen or the like; W1 is C1-C8 alkylene; W2 is a single bond or C1-C8 alkylene; X is hydrogen or the like; Y is oxygen or the like; and Z1 is alkoxy or the like] are prepared Feed containing 0.01%

3-[4-[6-(3,5-di-tert-butyl-4-hydroxyphenylthio)-1-methyl-1H-benzimidazol-2-ylmethoxy]phenyl]-2-(4-fluorobenzoyloxy)propionic acid decreased blood sugar in diabetic mice by 40.8%. Formulations are given.


IT 299175-43-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzimidazolylalkoxyphenylalkanoic acid derivs. for treatment of diabetes and other diseases)

RN 299175-43-2 HCAPLUS

CN L-Tyrosine, O-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 299176-09-3


RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of benzimidazolylalkoxyphenylalkanoic acid derivs. for

Updated Search



treatment of diabetes and other diseases)  
 RN 299176-09-3 HCAPLUS  
 CN L-Tyrosine, O-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:117035 HCAPLUS  
 DOCUMENT NUMBER: 132:151814  
 TITLE: Preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators  
 INVENTOR(S): Collins, Jon Loren; Dezube, Milana; Oplinger, Jeffrey Alan; Willson, Timothy Mark  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 110 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000008002	A1	20000217	WO 1999-EP5666	19990805
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339773	A1	20000217	CA 1999-2339773	19990805
AU 9957310	A	20000228	AU 1999-57310	19990805
EP 1102757	A1	20010530	EP 1999-944335	19990805
EP 1102757	B1	20040414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100372	T2	20010921	TR 2001-200100372	19990805
BR 9912866	A	20011030	BR 1999-12866	19990805
HU 200103469	A2	20020128	HU 2001-3469	19990805
EE 200100074	A	20020617	EE 2001-74	19990805
AT 264313	T	20040415	AT 1999-944335	19990805
ES 2220110	T3	20041201	ES 1999-944335	19990805
ZA 2001000983	A	20020305	ZA 2001-983	20010205
NO 2001000628	A	20010406	NO 2001-628	20010206

Updated Search




MX 2001PA01419	A	20010930	MX 2001-PA1419	20010207
HR 2001000095	A1	20020228	HR 2001-95	20010207
US 6498174	B1	20021224	US 2001-762445	20010222
IN 2001KN00166	A	20050311	IN 2001-KN166	20010313

PRIORITY APPLN. INFO.:

GB 1998-17118	A	19980807
WO 1999-EP5666	W	19990805

OTHER SOURCE(S): MARPAT 132:151814  
GI



AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, haloalkyl; R3 = alkyl, cycloalkyl, cycloalkenyl, etc.; R4 = (un)substituted 5-6 membered heterocyclyl containing at least one O, N or S atom, Ph; R5 = H, halo, alkyl, haloalkyl; R6 = H, alkyl; X = O, S; n = 1-3], which are dual activators of hPPAR $\gamma$  and hPPAR $\alpha$ , were prepared Thus, refluxing a suspension of (2S)-2-amino-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}propanoic acid (preparation given) and benzoylacetone in MeOH and trimethylorthoformate afforded 43% (2S)-(Z)-I [R1 = H; R2 = Me; R3 = Ph; R4 = Ph; R5 = H; R6 = Me; X = O; n = 2] which showed 39% glucose reduction in rats.

IT 258347-27-2  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators)

RN 258347-27-2 HCAPLUS


CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 185679-35-0

CMF C21 H22 N2 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1

Updated Search

CMF C2 H F3 O2



IT 185679-35-0P 258346-81-5P 258346-84-8P  
258346-85-9P 258346-86-0P 258346-87-1P  
258346-88-2P 258346-89-3P 258346-91-7P  
258346-92-8P 258346-94-0P 258346-96-2P  
258346-98-4P 258347-07-8P 258347-09-0P  
258347-11-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR  
alpha activators)

RN 185679-35-0 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 258346-81-5 HCAPLUS

CN L-Tyrosine, O-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 258346-84-8 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-thiazolyl)ethyl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.

Updated Search




RN 258346-85-9 HCAPLUS  
 CN L-Tyrosine, O-[2-[2-(4-fluorophenyl)-5-methyl-4-thiazolyl]ethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 258346-86-0 HCAPLUS  
 CN L-Tyrosine, O-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 258346-87-1 HCAPLUS  
 CN L-Tyrosine, O-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258346-88-2 HCAPLUS  
 CN L-Tyrosine, O-[2-[5-methyl-2-[4-(1-methylethoxy)phenyl]-4-oxazolyl]ethyl]-

Updated Search

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258346-89-3 HCAPLUS

CN L-Tyrosine, O-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258346-91-7 HCAPLUS

CN L-Tyrosine, O-[2-(2-phenyl-5-propyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258346-92-8 HCAPLUS

CN L-Tyrosine, O-[(5-methyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258346-94-0 HCAPLUS

Updated Search


CN L-Tyrosine, O-[2-[5-ethyl-2-(4-fluorophenyl)-4-thiazolyl]ethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 258346-96-2 HCAPLUS  
CN L-Tyrosine, O-[2-(5-ethyl-2-phenyl-4-thiazolyl)ethyl]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 258346-98-4 HCAPLUS  
CN L-Tyrosine, O-[2-[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]ethyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 258347-07-8 HCAPLUS  
CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-oxazolyl)methyl]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 258347-09-0 HCAPLUS

CN L-Tyrosine, O-[(5-ethyl-2-phenyl-4-thiazolyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258347-11-4 HCAPLUS

CN L-Tyrosine, O-[[5-ethyl-2-(4-fluorophenyl)-4-oxazolyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:77060 HCAPLUS

DOCUMENT NUMBER: 126:89361

TITLE: Preparation of (oxazolyl)alkoxyphenylpropionic acid derivatives as hypoglycemics and hypolipemics

INVENTOR(S): Takeno, Hidekazu; Ikemoto, Tomoyuki; Saitoh, Isao; Watanabe, Kazuhiro

PATENT ASSIGNEE(S): Sumitomo Metal Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

Updated Search

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9638415	A1	19961205	WO 1996-JP1380	19960524
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
JP 08325263	A	19961210	JP 1995-133460	19950531
AU 9657791	A	19961218	AU 1996-57791	19960524
PRIORITY APPLN. INFO.:			JP 1995-133460	A 19950531
			WO 1996-JP1380	W 19960524
OTHER SOURCE(S):	MARPAT	126:89361		
GI				




AB The title compds. I [A represents a nitrogenous heterocycle; W represents oxygen or carbonyl; R1 represents hydroxy, an ester residue or a substituted imide group; and R2 and R3 represent each hydrogen, alkyl, aralkyl, alkanoyl, benzoyl, etc.; R4 = H, nitro, etc.; m = 0 - 2] are prepared The title compds. at 10 mg/kg gave 32 to 54% decrease of blood glucose in diabetic mice.

IT 185679-35-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

RN 185679-35-0 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1983:13648 HCAPLUS  
DOCUMENT NUMBER: 98:13648  
TITLE: Chemical and biochemical properties of p-cresol  
methylhydroxylase  
AUTHOR(S): McIntire, William S.; Hopper, D. J.; Edmondson, D. E.;  
Singer, Thomas P.



Updated Search



AB Flavin peptides (generated by peptic digestion) were isolated from p-cresol methylhydroxylases (I) from several *Pseudomonas putida* strains and characterized. Peptide sequencing revealed N-dansyl-tyrosine as the N-terminal amino acid derivative. Apparently, the phenolic O of the tyrosine residue is blocked by the flavin. The flavin was associated with tyrosine with a molar ratio of 1:1. The putative 8 $\alpha$ -tyrosylflavin peptide was synthesized in its riboflavin form and judged identical with the isolated aminoacyl riboflavin (the flavin occurs naturally as FAD in I). Reduction of the 8 $\alpha$ -O-tyrosylflavin by Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>, followed by reoxidn. resulted in the release of tyrosine. In I, tyrosine was not released by reduction-oxidation, indicating the stabilization of the tyrosine-flavin linkage in the holoenzyme. Titration with p-cresol gave virtually the same results. As the substrate donates electrons (e-) in pairs but I accepts 3 e-, interenzymic e- transfer might be implicated.

NC(C(=O)O)CCc1ccc(OCC2=CC=C(C=C2)N3C(=O)NC(=O)N3C4=CC=C(C=C4)C)cc1


Updated Search




L4 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1981:420324 HCAPLUS  
 DOCUMENT NUMBER: 95:20324  
 TITLE: 8α-(O-Tyrosyl)flavin adenine dinucleotide, the  
 prosthetic group of bacterial p-cresol  
 methylhydroxylase  
 AUTHOR(S): McIntire, William; Edmondson, Dale E.; Hopper, David  
 J.; Singer, Thomas P.  
 CORPORATE SOURCE: Mol. Biol. Div., VA Med. Cent., San Francisco, CA,


94121, USA  
 SOURCE: Biochemistry (1981), 20(11), 3068-75  
 CODEN: BICHAW; ISSN: 0006-2960  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB 8 $\alpha$ (O-Tyrosyl)riboflavin (I) has been synthesized by condensation of the Cu(II) complex of L-tyrosine with 8 $\alpha$ -bromotetraacetylriboflavin. The structure of I was proven by absorption and <sup>1</sup>H NMR spectroscopy and by chemical degradation, which yielded 1 mol tyrosine/mol flavin. I comigrated with the (aminoacyl)riboflavin isolated from the p-cresol methylhydroxylase (II) of Pseudomonas putida, and both showed identical absorption and fluorescence spectral properties. I as well as the flavin-containing decapeptide from II undergoes reductive cleavage to form riboflavin and FAD, resp., on anaerobic treatment with dithionite. In contrast, native II, on reduction with dithionite, yields a reduced flavin via a red (anionic) flavosemiquinone intermediate, which remains covalently bound to the protein even under denaturing conditions. I bound to apoflavodoxin is also not cleaved on reduction with dithionite, but, instead, a blue (neutral) semiquinone of I is generated, which is resistant to further reduction with dithionite. Three II activities, isolated from different strains of Pseudomonas putida, differing in mol. weight and Km values for substrates, contain the same peptide at the flavin site. These data provide definitive proof for the existence of I in nature.  
 IT 74850-08-1  
 RL: BIOL (Biological study)  
 (as p-cresol methylhydroxylase prosthetic group)  
 RN 74850-08-1 HCAPLUS  
 CN Riboflavin 5'-(trihydrogen diphosphate),  $\alpha$ 8-[4-(2-amino-2-carboxyethyl)phenoxy]-, P' $\rightarrow$ 5'-ester with adenosine, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A





IT 38065-74-6P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and properties of)  
 RN 38065-74-6 HCAPLUS  
 CN Riboflavin,  $\alpha$ 8-[4-(2-amino-2-carboxyethyl)phenoxy]-, (S)- (9CI) (CA  
 INDEX NAME)



L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1980:527842 HCAPLUS  
 DOCUMENT NUMBER: 93:127842  
 TITLE: 8 $\alpha$ -O-tyrosyl-FAD: a new form of covalently  
 bound flavin from p-cresol methylhydroxylase  
 AUTHOR(S): McIntire, William; Edmondson, Dale E.; Singer, Thomas  
 P.; Hopper, David J.  
 CORPORATE SOURCE: Mol. Biol. Div., VA Med. Cent., San Francisco, CA,  
 94121, USA  
 SOURCE: Journal of Biological Chemistry (1980), 255(14),  
 6553-5  
 CODEN: JBCHA3; ISSN: 0021-9258  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB p-Cresol methylhydroxylase from *Pseudomonas putida* contains covalently  
 bound flavin and a type c cytochrome. A flavin undecapeptide was isolated  
 from peptic digests of the protein which shows the typical 3-banded

spectrum of flavins with the 2nd absorption peak shifted hypsochromically to 360 nm, indicating substitution at position 8 $\alpha$ . Aminopeptidase digestion gave an aminoacyl flavin, with a further shift of the 2nd band to 352 nm at neutral pH. The dinucleotide nature of the flavin was indicated by a major change in mobility in TLC on treatment of the peptide with nucleotide pyrophosphatase and a further change on subsequent dephosphorylation with alkaline phosphatase. The fluorescence of the peptide is trivial, but oxidation with performic acid at 0 and 40° for 1 h increased it to .apprx.10 and 35% of that of riboflavin, resp. Despite this indication that the compound may be a flavin thioether, no cysteine was detected in the peptide. The performic acid-oxidized flavin peptide showed no pH dependence of the fluorescence in the range pH 3.2-7, and, in accord with this, no histidine was present in hydrolyzates. The flavin was identified as 8 $\alpha$ -O-tyrosylriboflavin on the basis of the following evidence: dansylation of the flavin and acid hydrolysis yielded N-dansyltyrosine, instead of the expected O-dansyl or N,O-didansyltyrosine. Brief hydrolysis of the flavin peptide with aminopeptidase M gave an aminoacyl flavin which contained riboflavin and tyrosine in equal amts. 8 $\alpha$ -O-Tyrosyl-FAD is the N-terminal residue of the peptide. Noncovalent interaction between the flavin and this tyrosine, as well as a tryptophan residue, seems responsible for the virtually complete quenching of the fluorescence.

IT 74850-08-1


RL: BIOL (Biological study)


(as cresol 4-methylhydroxylase prosthetic group)

RN 74850-08-1 HCAPLUS

CN Riboflavin 5'-(trihydrogen diphosphate),  $\alpha$ 8-[4-(2-amino-2-carboxyethyl)phenoxy]-, P' $\rightarrow$ 5'-ester with adenosine, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A





L4 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1972:448772 HCAPLUS

DOCUMENT NUMBER: 77:48772

TITLE: Synthesis and properties of 8α-substituted riboflavines of biological importance

AUTHOR(S): Kenney, William C.; Walker, Wolfram H.

CORPORATE SOURCE: Mol. Biol. Div., Veterans Adm. Hosp., San Francisco, CA, USA

SOURCE: FEBS Letters (1972), 20(3), 297-301

CODEN: FEBLAL; ISSN: 0014-5793

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB 8α-Substituted riboflavines (I,II, III, and IV) were prepared Thus, 8α-bromotetraacetylriboflavine (V) was reacted with α-(N-benzoyl)-L-lysine amide acetate in DMF to give a product which on hydrolysis gave 8α-(Nε-lysyl)riboflavine (I). Similarly prepared were 8α-(O-tyrosyl)riboflavine (II) and 8α-sulforiboflavine (III). The carboxylic acid (IV) was obtained from V by performic acid oxidation Properties of I, II, III, and IV are compared with those of some other 8α-substituted riboflavines.

IT 38065-74-6P 38065-77-9P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 38065-74-6 HCAPLUS

CN Riboflavin, α8-[4-(2-amino-2-carboxyethyl)phenoxy]-, (S)- (9CI) (CA INDEX NAME)



RN 38065-77-9 HCAPLUS  
 CN Riboflavin,  $\alpha$ 8-[4-(2-amino-2-carboxyethyl)phenoxy]-,  
 2',3',4',5'-tetraacetate, (S)- (9CI) (CA INDEX NAME)



=> file caold  
 COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
125.99	301.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE ENTRY	TOTAL SESSION
-13.26	-13.26

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 35 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007

L4 17 S L3

L5 0 S L4 AND CHUPAK, L?/AU

Updated Search



L6 0 S L4 AND BOYER, F?/AU  
L7 0 S L4 AND HAGEN, S?/AU  
L8 0 S L4 AND KANEKO, T?/AU  
L9 0 S L4 AND LALL, M?/AU  
L10 32 S 4 AND PETTERSSON, M?/AU  
L11 0 S L4 AND LALL, M?/AU  
L12 0 S L4 AND PETTERSSON, M?/AU  
L13 0 S L4 AND PRASAD, J?/AU

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007

=> s 13

L14 0 L3

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	301.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.26

FILE 'REGISTRY' ENTERED AT 22:11:45 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1  
DICTIONARY FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\awawer.str

L15 STRUCTURE UPLOADED

=> s 115

SAMPLE SEARCH INITIATED 22:17:45 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 44624 TO ITERATE

4.5% PROCESSED 2000 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.11

Updated Search

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 879867 TO 905093  
PROJECTED ANSWERS: 37042 TO 42388

L16 50 SEA SSS SAM L15

=> s l16 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 22:18:10 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 892167 TO ITERATE

100.0% PROCESSED 892167 ITERATIONS 42185 ANSWERS  
SEARCH TIME: 00.00.09

L17 42185 SEA SSS FUL L15

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	176.60	478.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.26

FILE 'HCAPLUS' ENTERED AT 22:18:23 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2007 VOL 147 ISS 14  
FILE LAST UPDATED: 23 Sep 2007 (20070923/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l17/rct

23770 L17  
3017608 RCT/RL  
L18 5073 L17/RCT  
(L17 (L) RCT/RL)

=> d his

(FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007)

Updated Search

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007

L1 STRUCTURE UPLOADED  
L2 2 S L1  
L3 35 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007

L4 17 S L3  
L5 0 S L4 AND CHUPAK, L?/AU  
L6 0 S L4 AND BOYER, F?/AU  
L7 0 S L4 AND HAGEN, S?/AU  
L8 0 S L4 AND KANEKO, T?/AU  
L9 0 S L4 AND LALL, M?/AU  
L10 32 S 4 AND PETTERSSON, M?/AU  
L11 0 S L4 AND LALL, M?/AU  
L12 0 S L4 AND PETTERSSON, M?/AU  
L13 0 S L4 AND PRASAD, J?/AU

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007

L14 0 S L3

FILE 'REGISTRY' ENTERED AT 22:11:45 ON 24 SEP 2007

L15 STRUCTURE UPLOADED  
L16 50 S L15  
L17 42185 S L16 FULL

FILE 'HCAPLUS' ENTERED AT 22:18:23 ON 24 SEP 2007

L18 5073 S L17/RCT

=> s l18 and l4

L19 10 L18 AND L4

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.20	483.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.26

FILE 'REGISTRY' ENTERED AT 22:19:19 ON 24 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1

DICTIONARY FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

Updated Search


experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>  
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\awerth.str

L20 STRUCTURE UPLOADED

=> d 120  
L20 HAS NO ANSWERS  
L20 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 120  
SAMPLE SEARCH INITIATED 22:21:17 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 46807 TO ITERATE

4.3% PROCESSED 2000 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 923225 TO 949055  
PROJECTED ANSWERS: 42544 TO 48260

L21 50 SEA SSS SAM L20

=> s 120 full  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 22:21:22 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 934770 TO ITERATE

100.0% PROCESSED 934770 ITERATIONS 46885 ANSWERS  
SEARCH TIME: 00.00.08

L22 46885 SEA SSS FUL L20

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.45	657.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
--	------------	-------

Updated Search

CA SUBSCRIBER PRICE

ENTRY	SESSION
0.00	-13.26

FILE 'HCAPLUS' ENTERED AT 22:21:33 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2007 VOL 147 ISS 14  
FILE LAST UPDATED: 23 Sep 2007 (20070923/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 122/rct
      27391 L22
      3017608 RCT/RL
L23    6111 L22/RCT
      (L22 (L) RCT/RL)
```

=> d his

(FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007

```
L1      STRUCTURE UPLOADED
L2      2 S L1
L3      35 S L1 FULL
```

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007

```
L4      17 S L3
L5      0 S L4 AND CHUPAK, L?/AU
L6      0 S L4 AND BOYER, F?/AU
L7      0 S L4 AND HAGEN, S?/AU
L8      0 S L4 AND KANEKO, T?/AU
L9      0 S L4 AND LALL, M?/AU
L10     32 S 4 AND PETTERSSON, M?/AU
L11     0 S L4 AND LALL, M?/AU
L12     0 S L4 AND PETTERSSON, M?/AU
L13     0 S L4 AND PRASAD, J?/AU
```

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007

```
L14     0 S L3
```

FILE 'REGISTRY' ENTERED AT 22:11:45 ON 24 SEP 2007

```
L15     STRUCTURE UPLOADED
L16     50 S L15
L17     42185 S L16 FULL
```

Updated Search

FILE 'HCAPLUS' ENTERED AT 22:18:23 ON 24 SEP 2007  
L18 5073 S L17/RCT  
L19 10 S L18 AND L4

FILE 'REGISTRY' ENTERED AT 22:19:19 ON 24 SEP 2007  
L20 STRUCTURE UPLOADED  
L21 50 S L20  
L22 46885 S L20 FULL



FILE 'HCAPLUS' ENTERED AT 22:21:33 ON 24 SEP 2007  
L23 6111 S L22/RCT

=> s 123 and 119  
L24 3 L23 AND L19

=> d 124, ibib abs hitstr, 1-3

L24 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:1016040 HCAPLUS  
DOCUMENT NUMBER: 141:424180  
TITLE: Processes for making thiazolidinedione derivatives and  
compounds thereof  
INVENTOR(S): Pospisilik, Karel; Zhu, Jie; Picha, Frantisek  
PATENT ASSIGNEE(S): Synthon B.V., Neth.  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101560	A1	20041125	WO 2004-EP5026	20040511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005059708	A1	20050317	US 2004-842635	20040511
EP 1622898	A1	20060208	EP 2004-732115	20040511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812988	A	20060802	CN 2004-80018359	20040511
JP 2007502847	T	20070215	JP 2006-529780	20040511
PRIORITY APPLN. INFO.:			US 2003-469837P	P 20030513
			WO 2004-EP5026	W 20040511
OTHER SOURCE(S):	MARPAT	141:424180		
GI				



AB The invention relates processes for the synthesis of thiazolidinedione derivs. I (A is ethyl-2-pyridylethyl, [(2-pyridyl)methylamino]ethyl or [3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methyl] via reactions of amino acid intermediates II (same A, R is H or alkyl, Q is H or an amine-protecting group). The synthesis of pioglitazone is illustrated. Thus, 2-amino-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]propionic acid, prepared by O-alkylation of L-tyrosine, underwent diazotization reaction to give the 2-bromo derivative which underwent cyclocondensation with thiourea to afford pioglitazone (isolated as the HCl salt).


IT 5223-06-3 144809-27-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(Processes for making thiazolidinedione derivs. and compds. thereof)


RN 5223-06-3 HCAPLUS

CN 2-Pyridineethanol, 5-ethyl- (CA INDEX NAME)



RN 144809-27-8 HCAPLUS

CN 2-Pyridineethanol, 5-ethyl-, 4-methylbenzenesulfonate (ester) (9CI) (CA INDEX NAME)



IT 537-55-3P, n Acetyl L-Tyrosine 840-97-1P, n Acetyl

L-Tyrosine ethyl ester 105355-26-8P 124731-84-6P

144809-26-7P 674798-32-4P 794591-56-3P

794591-57-4P 794591-58-5P 794591-59-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP


(Preparation); RACT (Reactant or reagent)

(Processes for making thiazolidinedione derivs. and compds. thereof)

RN 537-55-3 HCAPLUS


CN L-Tyrosine, N-acetyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 840-97-1 HCAPLUS  
 CN L-Tyrosine, N-acetyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 105355-26-8 HCAPLUS  
 CN 4(5H)-Thiazolone, 2-amino-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)




RN 124731-84-6 HCAPLUS  
 CN L-Tyrosine, N-acetyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 144809-26-7 HCAPLUS  
 CN 2-Pyridineethanol, 5-ethyl-, methanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 674798-32-4 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(5-ethyl-2-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 794591-56-3 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 794591-57-4 HCAPLUS  
 CN L-Tyrosine, N-acetyl-O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 794591-58-5 HCAPLUS  
 CN L-Tyrosine, N-acetyl-O-[2-(5-ethyl-2-pyridinyl)ethyl]-, 1-methylethyl

Updated Search


ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 794591-59-6 HCAPLUS

CN Benzenepropanoic acid, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-α-thiocyanato- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:996131 HCAPLUS

DOCUMENT NUMBER: 141:424428

TITLE: Intermediate compound, namely O-[2-(5-ethylpyridin-2-yl)ethyl]tyrosine, which is used for the preparation of the antidiabetic agent pioglitazone, and methods for its preparation and conversion to pioglitazone

INVENTOR(S): Duran, Lopez Ernesto

PATENT ASSIGNEE(S): Medichem, S.A., Spain

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish





FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099147	A1	20041118	WO 2004-ES70031	20040504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2219180	A1	20041116	ES 2003-1075	20030509
ES 2219180	B1	20060301		
CA 2525190	A1	20041118	CA 2004-2525190	20040504
EP 1623977	A1	20060208	EP 2004-731028	20040504

Updated Search

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 US 2007083050 A1 20070412 US 2006-555659 20061219  
 PRIORITY APPLN. INFO.: ES 2003-1075 A 20030509  
 WO 2004-ES70031 W 20040504  
 OTHER SOURCE(S): CASREACT 141:424428; MARPAT 141:424428  
 GI



AB The invention relates to the novel O-substituted tyrosine derivative I, including pure or mixed enantiomers, racemates, salts, solvates, and hydrates. I and its stereoisomers and compds. are new key intermediates for the preparation of the antidiabetic agent pioglitazone (II). The invention also relates to a method of obtaining I from a natural product, L-tyrosine, in which the amino group, in the form of an aromatic imine group, is protected by an aldehyde or ketone. The invention further relates to a method of obtaining II from the intermediate compound I. The critical feature of the invention is protection of the tyrosine N-terminal as an imine, which allows etherification of the phenolic tyrosine OH group to occur without competing N-alkylation. Complete racemization during the process allows the more desirable racemic I to be prepared from the more readily available L-tyrosine. For instance, L-tyrosine was treated with SOCl<sub>2</sub> in refluxing MeOH to give the Me ester, which was treated with PhCHO at room temperature in CH<sub>2</sub>Cl<sub>2</sub> to give doubly protected tyrosine III. This phenolic compound was etherified with the mesylate IV (preparation given) using K<sub>2</sub>CO<sub>3</sub>

and

Bu<sub>4</sub>N<sup>+</sup>Br<sup>-</sup> in PhMe at 70°, and the protected product was deprotected in situ first with acid (2N HCl) and then with base (50% NaOH), both at 70°, to give racemic I in 62.8% overall yield from L-tyrosine. Diazotization of the amino group in I in the presence of HBr gave the corresponding bromo compound, which was cyclized with thiourea to give the

2-imine derivative of II. Acid hydrolysis of the imine in refluxing aqueous HCl


gave II in 40.7% yield from I. Four comparative processes for preparing I, using other standard amine protecting groups instead of a benzaldehyde imine, were examined. Overall yields of I from L-tyrosine were 24.1% for Boc, 20.7% for Cbz, 11.5% for Ac, and poor (unisolated) for EtOCO, vs. 62.8% for benzylidene.

IT 2440-79-1P, N-Acetyl-L-tyrosine methyl ester 4326-36-7P, N-Boc-L-tyrosine methyl ester 13512-31-7P, N-Cbz-L-tyrosine methyl ester 215596-38-6P, N-(Ethoxycarbonyl)-L-tyrosine methyl ester 795316-23-3P, N-Boc-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine methyl ester 795316-24-4P, N-Boc-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine 795316-25-5P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-L-tyrosine methyl ester 795316-26-6P, N-Cbz-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine methyl ester  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(comparison process intermediate; intermediate compound which is used for the preparation of pioglitazone)

RN 2440-79-1 HCAPLUS

CN L-Tyrosine, N-acetyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 4326-36-7 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 13512-31-7 HCAPLUS


CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 215596-38-6 HCAPLUS  
 CN L-Tyrosine, N-(ethoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 795316-23-3 HCAPLUS  
 CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-[2-(5-ethyl-2-pyridinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 795316-24-4 HCAPLUS  
 CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 795316-25-5 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Updated Search

INDEX NAME)


Absolute stereochemistry.



RN 795316-26-6 HCAPLUS

CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]-N-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 69955-04-0P, N-Benzylidene-L-tyrosine methyl ester

105355-26-8P, Pioglitazone 2-imine 144809-26-7P,

2-(5-Ethylpyridin-2-yl)ethyl methanesulfonate 674798-32-4P,

α-Bromo-4-[2-(5-ethylpyridin-2-yl)ethoxy]benzenepropanoic acid

795316-28-8P, N-Benzylidene-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine methyl ester

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(process intermediate; intermediate compound which is used for the preparation of pioglitazone)

RN 69955-04-0 HCAPLUS

CN L-Tyrosine, N-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.




RN 105355-26-8 HCAPLUS

CN 4(5H)-Thiazolone, 2-amino-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (CA INDEX NAME)


Updated Search



RN 144809-26-7 HCAPLUS  
 CN 2-Pyridineethanol, 5-ethyl-, methanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 674798-32-4 HCAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -bromo-4-[2-(5-ethyl-2-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 795316-28-8 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]-N-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.


Updated Search



IT 5223-06-3, 2-(5-Ethylpyridin-2-yl)ethanol  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; intermediate compound which is used for the preparation  
 of pioglitazone)  
 RN 5223-06-3 HCAPLUS  
 CN 2-Pyridineethanol, 5-ethyl- (CA INDEX NAME)




IT 795316-22-2P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-DL-tyrosine  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic  
 preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (target intermediate; intermediate compound which is used for the  
 preparation of pioglitazone)  
 RN 795316-22-2 HCAPLUS  
 CN Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 794591-56-3P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-L-tyrosine  
 795316-27-7P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-D-tyrosine  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (target intermediate; intermediate compound which is used for the  
 preparation of pioglitazone)  
 RN 794591-56-3 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 795316-27-7 HCAPLUS

Updated Search



CN D-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1997:77060 HCAPLUS  
DOCUMENT NUMBER: 126:89361  
TITLE: Preparation of (oxazolyl)alkoxyphenylpropionic acid derivatives as hypoglycemics and hypolipemics  
INVENTOR(S): Takeno, Hidekazu; Ikemoto, Tomoyuki; Saitoh, Isao; Watanabe, Kazuhiro  
PATENT ASSIGNEE(S): Sumitomo Metal Industries, Ltd., Japan  
SOURCE: PCT Int. Appl., 94 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9638415	A1	19961205	WO 1996-JP1380	19960524
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
JP 08325263	A	19961210	JP 1995-133460	19950531
AU 9657791	A	19961218	AU 1996-57791	19960524
PRIORITY APPLN. INFO.:			JP 1995-133460	A 19950531
			WO 1996-JP1380	W 19960524
OTHER SOURCE(S):		MARPAT 126:89361		
GI				



AB The title compds. I [A represents a nitrogenous heterocycle; W represents oxygen or carbonyl; R1 represents hydroxy, an ester residue or a substituted imide group; and R2 and R3 represent each hydrogen, alkyl, aralkyl, alkanoyl, benzoyl, etc.; R4 = H, nitro, etc.; m = 0 - 2] are prepared The title compds. at 10 mg/kg gave 32 to 54% decrease of blood glucose in diabetic mice.  
IT 185679-35-0P


Updated Search

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

RN 185679-35-0 HCAPLUS

CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 5223-06-3, 2-(5-Ethyl-2-pyridyl)ethanol 72594-77-5  
185679-62-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of (oxazolyl)alkoxyphenylpropionic acid derivs. as hypoglycemics and hypolipemics)

RN 5223-06-3 HCAPLUS


CN 2-Pyridineethanol, 5-ethyl- (CA INDEX NAME)



RN 72594-77-5 HCAPLUS


CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 185679-62-3 HCAPLUS

CN Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 185679-57-6P 185679-58-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP  
 (Preparation); RACT (Reactant or reagent)  
 (preparation of (oxazolyl)alkoxyphenylpropionic acid derivs. as  
 hypoglycemics and hypolipemics)  
 RN 185679-57-6 HCAPLUS  
 CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-[2-(5-ethyl-2-  
 pyridinyl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185679-58-7 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]-N-(trifluoroacetyl)-, ethyl  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file caold  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
18.41	675.56

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.34	-15.60

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 22:22:11 ON 24 SEP 2007

Updated Search

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007

L1 STRUCTURE UPLOADED  
L2 2 S L1  
L3 35 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007

L4 17 S L3  
L5 0 S L4 AND CHUPAK, L?/AU  
L6 0 S L4 AND BOYER, F?/AU  
L7 0 S L4 AND HAGEN, S?/AU  
L8 0 S L4 AND KANEKO, T?/AU  
L9 0 S L4 AND LALL, M?/AU  
L10 32 S 4 AND PETTERSSON, M?/AU  
L11 0 S L4 AND LALL, M?/AU  
L12 0 S L4 AND PETTERSSON, M?/AU  
L13 0 S L4 AND PRASAD, J?/AU

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007

L14 0 S L3

FILE 'REGISTRY' ENTERED AT 22:11:45 ON 24 SEP 2007

L15 STRUCTURE UPLOADED  
L16 50 S L15  
L17 42185 S L16 FULL

FILE 'HCAPLUS' ENTERED AT 22:18:23 ON 24 SEP 2007

L18 5073 S L17/RCT  
L19 10 S L18 AND L4

FILE 'REGISTRY' ENTERED AT 22:19:19 ON 24 SEP 2007

L20 STRUCTURE UPLOADED  
L21 50 S L20  
L22 46885 S L20 FULL

FILE 'HCAPLUS' ENTERED AT 22:21:33 ON 24 SEP 2007

L23 6111 S L22/RCT  
L24 3 S L23 AND L19

Updated Search

FILE 'CAOLD' ENTERED AT 22:22:11 ON 24 SEP 2007

=> s 122 and 117  
1210 L22  
581 L17  
L25 0 L22 AND L17

=>

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	1.80	677.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-15.60

FILE 'REGISTRY' ENTERED AT 22:24:21 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1  
DICTIONARY FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e pioglitazone/cn  
E1 1 PIOESTER 4248, POLYMER WITH 1,3,5-TRIS(OXIRANYLMETHYL)-1,3,5  
-TRIAZINE-2,4,6(1H,3H,5H)-TRIONE/CN  
E2 1 PIOESTER 4350-55/CN  
E3 1 --> PIOGLITAZONE/CN  
E4 1 PIOGLITAZONE 2-IMINE/CN  
E5 1 PIOGLITAZONE HYDROCHLORIDE/CN  
E6 1 PIOGLITAZONE N-OXIDE/CN  
E7 1 PIOGLITAZONE NITRATE/CN  
E8 1 PIOKTANIN/CN  
E9 1 PIOLENE 1802/CN  
E10 1 PIOLOFORM BL 16/CN  
E11 1 PIOLOFORM BL 18/CN  
E12 1 PIOLOFORM BL 24/CN

=> s e3  
L26 1 PIOGLITAZONE/CN

Updated Search

=> d 126

L26 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 111025-46-8 REGISTRY

ED Entered STN: 31 Oct 1987

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
, (±)-

OTHER NAMES:

CN 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione

CN Pioglitazone

CN U 72107

CN Zactos

DR 105355-27-9, 198077-89-3

MF C19 H20 N2 O3 S


CI COM

SR US Adopted Names Council (USAN)

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS,  
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,  
DRUGU, EMBASE, HSDB\*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,  
MEDLINE, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH,  
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO

PAGE 1-A



|  
Et

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1727 REFERENCES IN FILE CA (1907 TO DATE)  
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1739 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

=>


Uploading C:\Documents and Settings\brobinson1\My  
Documents\stnweb\Queries\asdfadsm.str

L27        STRUCTURE UPLOADED

=> d 127

L27 HAS NO ANSWERS

L27                STR



Structure attributes must be viewed using STN Express query preparation.

=> s 127

SAMPLE SEARCH INITIATED 22:46:09 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -        6187 TO ITERATE

32.3% PROCESSED        2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                              BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:        119024 TO    128456  
PROJECTED ANSWERS:            0 TO        0

Updated Search



L28 0 SEA SSS SAM L27

=> s 127 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 22:46:14 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 122592 TO ITERATE

100.0% PROCESSED 122592 ITERATIONS 5 ANSWERS  
SEARCH TIME: 00.00.02

L29 5 SEA SSS FUL L27

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	195.20	872.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.60

FILE 'HCAPLUS' ENTERED AT 22:46:22 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS).

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2007 VOL 147 ISS 14  
FILE LAST UPDATED: 23 Sep 2007 (20070923/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 129

L30 4 L29

=> s 129/rct

4 L29  
3018046 RCT/RL  
L31 2 L29/RCT  
(L29 (L) RCT/RL)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	875.16
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

Updated Search

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-15.60

FILE 'REGISTRY' ENTERED AT 22:46:34 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1  
DICTIONARY FILE UPDATES: 23 SEP 2007 HIGHEST RN 947726-74-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\aqwe.str

L32 STRUCTURE UPLOADED

=> s 132  
SAMPLE SEARCH INITIATED 22:51:41 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 327 TO ITERATE

100.0% PROCESSED	327 ITERATIONS	1 ANSWERS
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	5456 TO	7624
PROJECTED ANSWERS:	1 TO	80

L33 1 SEA SSS SAM L32

=> s 132 full  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 22:51:45 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 6273 TO ITERATE

100.0% PROCESSED	6273 ITERATIONS	70 ANSWERS
SEARCH TIME: 00.00.01		

L34 70 SEA SSS FUL L32

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION

Updated Search

FULL ESTIMATED COST	175.70	1050.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.60

FILE 'HCAPLUS' ENTERED AT 22:51:50 ON 24 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Sep 2007 VOL 147 ISS 14  
 FILE LAST UPDATED: 23 Sep 2007 (20070923/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 134  
 L35 1870 L34

=> s 133/prep  
 1 L33  
 4465713 PREP/RL  
 L36 0 L33/PREP  
 (L33 (L) PREP/RL)

=> s 134/prep  
 1870 L34  
 4465713 PREP/RL  
 L37 58 L34/PREP  
 (L34 (L) PREP/RL)

=> d his

(FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007

L1 STRUCTURE UPLOADED  
 L2 2 S L1  
 L3 35 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007

L4 17 S L3  
 L5 0 S L4 AND CHUPAK, L?/AU  
 L6 0 S L4 AND BOYER, F?/AU  
 L7 0 S L4 AND HAGEN, S?/AU  
 L8 0 S L4 AND KANEKO, T?/AU  
 L9 0 S L4 AND LALL, M?/AU

Updated Search

L10 32 S 4 AND PETTERSSON, M?/AU  
L11 0 S L4 AND LALL, M?/AU  
L12 0 S L4 AND PETTERSSON, M?/AU  
L13 0 S L4 AND PRASAD, J?/AU

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007  
L14 0 S L3

FILE 'REGISTRY' ENTERED AT 22:11:45 ON 24 SEP 2007  
L15 STRUCTURE UPLOADED  
L16 50 S L15  
L17 42185 S L16 FULL

FILE 'HCAPLUS' ENTERED AT 22:18:23 ON 24 SEP 2007  
L18 5073 S L17/RCT  
L19 10 S L18 AND L4

FILE 'REGISTRY' ENTERED AT 22:19:19 ON 24 SEP 2007  
L20 STRUCTURE UPLOADED  
L21 50 S L20  
L22 46885 S L20 FULL

FILE 'HCAPLUS' ENTERED AT 22:21:33 ON 24 SEP 2007  
L23 6111 S L22/RCT  
L24 3 S L23 AND L19

FILE 'CAOLD' ENTERED AT 22:22:11 ON 24 SEP 2007  
L25 0 S L22 AND L17

FILE 'REGISTRY' ENTERED AT 22:24:21 ON 24 SEP 2007  
E PIOGLITAZONE/CN  
L26 1 S E3  
L27 STRUCTURE UPLOADED  
L28 0 S L27  
L29 5 S L27 FULL

FILE 'HCAPLUS' ENTERED AT 22:46:22 ON 24 SEP 2007  
L30 4 S L29  
L31 2 S L29/RCT

FILE 'REGISTRY' ENTERED AT 22:46:34 ON 24 SEP 2007  
L32 STRUCTURE UPLOADED  
L33 1 S L32  
L34 70 S L32 FULL

FILE 'HCAPLUS' ENTERED AT 22:51:50 ON 24 SEP 2007  
L35 1870 S L34  
L36 0 S L33/PREP  
L37 58 S L34/PREP

=> s l37 and l31  
L38 2 L37 AND L31



=> d l38, ibib abs hitstr, 1-2

L38 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:1016040 HCAPLUS  
DOCUMENT NUMBER: 141:424180  
TITLE: Processes for making thiazolidinedione derivatives and  
compounds thereof  
INVENTOR(S): Pospisilik, Karel; Zhu, Jie; Picha, Frantisek

Updated Search

PATENT ASSIGNEE(S): Synthon B.V., Neth.  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101560	A1	20041125	WO 2004-EP5026	20040511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005059708	A1	20050317	US 2004-842635	20040511
EP 1622898	A1	20060208	EP 2004-732115	20040511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1812988	A	20060802	CN 2004-80018359	20040511
JP 2007502847	T	20070215	JP 2006-529780	20040511
PRIORITY APPLN. INFO.:			US 2003-469837P	P 20030513
			WO 2004-EP5026	W 20040511
OTHER SOURCE(S):		MARPAT 141:424180		
GI				



AB The invention relates processes for the synthesis of thiazolidinedione derivs. I (A is ethyl-2-pyridylethyl, [(2-pyridyl)methylamino]ethyl or [3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methyl] via reactions of amino acid intermediates II (same A, R is H or alkyl, Q is H or an amine-protecting group). The synthesis of pioglitazone is illustrated. Thus, 2-amino-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]propionic acid, prepared by O-alkylation of L-tyrosine, underwent diazotization reaction to give the 2-bromo derivative which underwent cyclocondensation with thiourea to afford pioglitazone (isolated as the HCl salt).


IT 111025-46-8P, Pioglitazone 112529-15-4P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
 (Processes for making thiazolidinedione derivs. and compds. thereof)

RN 111025-46-8 HCAPLUS  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
 (CA INDEX NAME)



Et


RN 112529-15-4 HCAPLUS  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
 , hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 794591-56-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP  
 (Preparation); RACT (Reactant or reagent)  
 (Processes for making thiazolidinedione derivs. and compds. thereof)  
 RN 794591-56-3 HCAPLUS  
 CN L-Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:996131 HCAPLUS  
DOCUMENT NUMBER: 141:424428  
TITLE: Intermediate compound, namely O-[2-(5-ethylpyridin-2-yl)ethyl]tyrosine, which is used for the preparation of the antidiabetic agent pioglitazone, and methods for its preparation and conversion to pioglitazone  
INVENTOR(S): Duran, Lopez Ernesto  
PATENT ASSIGNEE(S): Medichem, S.A., Spain  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Spanish  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099147	A1	20041118	WO 2004-ES70031	20040504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2219180	A1	20041116	ES 2003-1075	20030509
ES 2219180	B1	20060301		
CA 2525190	A1	20041118	CA 2004-2525190	20040504
EP 1623977	A1	20060208	EP 2004-731028	20040504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2007083050	A1	20070412	US 2006-555659	20061219
PRIORITY APPLN. INFO.:			ES 2003-1075	A 20030509
			WO 2004-ES70031	W 20040504
OTHER SOURCE(S):				
GI				

CASREACT 141:424428; MARPAT 141:424428





AB The invention relates to the novel O-substituted tyrosine derivative I, including pure or mixed enantiomers, racemates, salts, solvates, and hydrates. I and its stereoisomers and compds. are new key intermediates for the preparation of the antidiabetic agent pioglitazone (II). The invention also relates to a method of obtaining I from a natural product, L-tyrosine, in which the amino group, in the form of an aromatic imine group, is protected by an aldehyde or ketone. The invention further relates to a method of obtaining II from the intermediate compound I. The critical feature of the invention is protection of the tyrosine N-terminal as an imine, which allows etherification of the phenolic tyrosine OH group to occur without competing N-alkylation. Complete racemization during the process allows the more desirable racemic I to be prepared from the more readily available L-tyrosine. For instance, L-tyrosine was treated with SOCl<sub>2</sub> in refluxing MeOH to give the Me ester, which was treated with PhCHO at room temperature in CH<sub>2</sub>Cl<sub>2</sub> to give doubly protected tyrosine III. This phenolic compound was etherified with the mesylate IV (preparation given) using K<sub>2</sub>CO<sub>3</sub>

and

Bu<sub>4</sub>N<sup>+</sup>Br<sup>-</sup> in PhMe at 70°, and the protected product was deprotected in situ first with acid (2N HCl) and then with base (50% NaOH), both at 70°, to give racemic I in 62.8% overall yield from L-tyrosine. Diazotization of the amino group in I in the presence of HBr gave the corresponding bromo compound, which was cyclized with thiourea to give the 2-imine derivative of II. Acid hydrolysis of the imine in refluxing aqueous

HCl

gave II in 40.7% yield from I. Four comparative processes for preparing I, using other standard amine protecting groups instead of a benzaldehyde imine, were examined. Overall yields of I from L-tyrosine were 24.1% for Boc, 20.7% for Cbz, 11.5% for Ac, and poor (unisolated) for EtOCO, vs. 62.8% for benzylidene.


IT 112529-15-4P, Pioglitazone hydrochloride

RL: SPN (Synthetic preparation); PREP (Preparation)

(intermediate compound which is used for the preparation of pioglitazone)

RN 112529-15-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 795316-22-2P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-DL-tyrosine  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic  
preparation); PREP (Preparation); RACT (Reactant or reagent)  
(target intermediate; intermediate compound which is used for the  
preparation  
of pioglitazone)

RN 795316-22-2 HCAPLUS


CN Tyrosine, O-[2-(5-ethyl-2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 111025-46-8P, Pioglitazone  
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
(Preparation)  
(target product; intermediate compound which is used for the preparation of  
pioglitazone)

RN 111025-46-8 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
(CA INDEX NAME)



|  
Et

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
18.34	1069.20

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.56	-17.16

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 22:53:38 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE

display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 21:58:30 ON 24 SEP 2007)

FILE 'REGISTRY' ENTERED AT 21:58:36 ON 24 SEP 2007

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 35 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 22:03:28 ON 24 SEP 2007

L4 17 S L3

L5 0 S L4 AND CHUPAK, L?/AU

L6 0 S L4 AND BOYER, F?/AU

L7 0 S L4 AND HAGEN, S?/AU

L8 0 S L4 AND KANEKO, T?/AU

L9 0 S L4 AND LALL, M?/AU

L10 32 S 4 AND PETTERSSON, M?/AU

L11 0 S L4 AND LALL, M?/AU

L12 0 S L4 AND PETTERSSON, M?/AU

L13 0 S L4 AND PRASAD, J?/AU

FILE 'CAOLD' ENTERED AT 22:11:39 ON 24 SEP 2007

L14 0 S L3

FILE 'REGISTRY' ENTERED AT 22:11:45 ON 24 SEP 2007

L15 STRUCTURE UPLOADED

L16 50 S L15

L17 42185 S L16 FULL

FILE 'HCAPLUS' ENTERED AT 22:18:23 ON 24 SEP 2007

L18 5073 S L17/RCT

L19 10 S L18 AND L4

FILE 'REGISTRY' ENTERED AT 22:19:19 ON 24 SEP 2007

L20 STRUCTURE UPLOADED

L21 50 S L20

L22 46885 S L20 FULL

FILE 'HCAPLUS' ENTERED AT 22:21:33 ON 24 SEP 2007

L23 6111 S L22/RCT

L24 3 S L23 AND L19

FILE 'CAOLD' ENTERED AT 22:22:11 ON 24 SEP 2007

L25 0 S L22 AND L17

FILE 'REGISTRY' ENTERED AT 22:24:21 ON 24 SEP 2007

E PIOGLITAZONE/CN

L26 1 S E3

L27 STRUCTURE UPLOADED

L28 0 S L27

L29 5 S L27 FULL

FILE 'HCAPLUS' ENTERED AT 22:46:22 ON 24 SEP 2007

Updated Search

L30 4 S L29  
L31 2 S L29/RCT

FILE 'REGISTRY' ENTERED AT 22:46:34 ON 24 SEP 2007

L32 STRUCTURE UPLOADED  
L33 1 S L32  
L34 70 S L32 FULL

FILE 'HCAPLUS' ENTERED AT 22:51:50 ON 24 SEP 2007

L35 1870 S L34  
L36 0 S L33/PREP  
L37 58 S L34/PREP  
L38 2 S L37 AND L31

FILE 'CAOLD' ENTERED AT 22:53:38 ON 24 SEP 2007

=> s 137 and 131

QUALIFICATION NOT VALID FOR L34

Field code qualifications can only be applied to text terms.

=> s 134 and 129

0 L34  
0 L29  
L39 0 L34 AND L29

=> file casreact

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.90	1070.10
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-17.16

FILE 'CASREACT' ENTERED AT 22:55:06 ON 24 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 22 Sep 2007 VOL 147 ISS 14

New CAS Information Use Policies, enter HELP USAGETERMS for details.

\*\*\*\*\*  
\*  
\* CASREACT now has more than 12 million reactions \*  
\*  
\*\*\*\*\*

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Updated Search

=>  
Uploading C:\Documents and Settings\brobinson1\My  
Documents\stnweb\Queries\asfsdfk.str

L40        STRUCTURE UPLOADED

=> s 140

SAMPLE SEARCH INITIATED 23:00:01 FILE 'CASREACT'  
SCREENING COMPLETE -            0 REACTIONS TO VERIFY FROM            0 DOCUMENTS  
  
100.0% DONE            0 VERIFIED            0 HIT RXNS            0 DOCS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                             BATCH    \*\*COMPLETE\*\*  
PROJECTED VERIFICATIONS:            0 TO            0  
PROJECTED ANSWERS:            0 TO            0

L41            0 SEA SSS SAM L40 (        0 REACTIONS)

=> s 140 full

THE ESTIMATED SEARCH COST FOR FILE 'CASREACT' IS 113.10 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 23:00:06 FILE 'CASREACT'  
SCREENING COMPLETE -            23 REACTIONS TO VERIFY FROM            4 DOCUMENTS  
  
100.0% DONE            23 VERIFIED            1 HIT RXNS            1 DOCS  
SEARCH TIME: 00.00.01

L42            1 SEA SSS FUL L40 (        1 REACTIONS)

=> d 142, all, 1

L42    ANSWER 1 OF 1    CASREACT    COPYRIGHT 2007 ACS on STN  
AN    141:424428    CASREACT  
TI    Intermediate compound, namely O-[2-(5-ethylpyridin-2-yl)ethyl]tyrosine,  
      which is used for the preparation of the antidiabetic agent pioglitazone,  
      and methods for its preparation and conversion to pioglitazone  
IN    Duran, Lopez Ernesto  
PA    Medichem, S.A., Spain  
SO    PCT Int. Appl., 26 pp.  
      CODEN: PIXXD2  
DT    Patent  
LA    Spanish  
IC    ICM    C07D213-55  
      ICS    C07D417-12; A61K031-44; A61P003-10  
CC    34-2 (Amino Acids, Peptides, and Proteins)  
      Section cross-reference(s): 27, 45  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099147	A1	20041118	WO 2004-ES70031	20040504
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

Updated Search





EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

ES 2219180	A1	20041116	ES 2003-1075	20030509
ES 2219180	B1	20060301		
CA 2525190	A1	20041118	CA 2004-2525190	20040504
EP 1623977	A1	20060208	EP 2004-731028	20040504

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2007083050	A1	20070412	US 2006-555659	20061219
---------------	----	----------	----------------	----------

PRAI ES 2003-1075 20030509  
WO 2004-ES70031 20040504  
OS MARPAT 141:424428  
GI



AB The invention relates to the novel O-substituted tyrosine derivative I, including pure or mixed enantiomers, racemates, salts, solvates, and hydrates. I and its stereoisomers and compds. are new key intermediates for the preparation of the antidiabetic agent pioglitazone (II). The invention also relates to a method of obtaining I from a natural product, L-tyrosine, in which the amino group, in the form of an aromatic imine group, is protected by an aldehyde or ketone. The invention further relates to a method of obtaining II from the intermediate compound I. The critical feature of the invention is protection of the tyrosine N-terminal as an imine, which allows etherification of the phenolic tyrosine OH group to occur without competing N-alkylation. Complete racemization during the process allows the more desirable racemic I to be prepared from the more readily available L-tyrosine. For instance, L-tyrosine was treated with SOCl<sub>2</sub> in refluxing MeOH to give the Me ester, which was treated with PhCHO at room temperature in CH<sub>2</sub>Cl<sub>2</sub> to give doubly protected tyrosine III. This phenolic



compound was etherified with the mesylate IV (preparation given) using K<sub>2</sub>CO<sub>3</sub> and Bu<sub>4</sub>N<sup>+</sup>Br<sup>-</sup> in PhMe at 70°, and the protected product was deprotected in situ first with acid (2N HCl) and then with base (50% NaOH), both at 70°, to give racemic I in 62.8% overall yield from L-tyrosine. Diazotization of the amino group in I in the presence of HBr gave the corresponding bromo compound, which was cyclized with thiourea to give the 2-imine derivative of II. Acid hydrolysis of the imine in refluxing aqueous HCl gave II in 40.7% yield from I. Four comparative processes for preparing I, using other standard amine protecting groups instead of a benzaldehyde imine, were examined. Overall yields of I from L-tyrosine were 24.1% for Boc, 20.7% for Cbz, 11.5% for Ac, and poor (unisolated) for EtOCO, vs. 62.8% for benzyldiene.

ST ethylpyridinylethyltyrosine prepn intermediate pioglitazone antidiabetic;  
 IT etherification imine protected tyrosine ester ethylpyridinylethyl mesylate  
 IT Antidiabetic agents  
 (intermediate compound which is used for the preparation of pioglitazone)  
 IT Amino acids, preparation  
 Schiff bases  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate compound which is used for the preparation of pioglitazone)  
 IT Etherification  
 Protective groups  
 (preparation of [(ethylpyridinyl)ethyl]tyrosine via etherification of imine-protected tyrosine and use as intermediate for pioglitazone)  
 IT 2440-79-1P, N-Acetyl-L-tyrosine methyl ester 4326-36-7P,  
 N-Boc-L-tyrosine methyl ester 13512-31-7P, N-Cbz-L-tyrosine methyl ester  
 215596-38-6P, N-(Ethoxycarbonyl)-L-tyrosine methyl ester 795316-23-3P,  
 N-Boc-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine methyl ester  
 795316-24-4P, N-Boc-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine  
 795316-25-5P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-L-tyrosine methyl ester  
 795316-26-6P, N-Cbz-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine methyl  
 ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (comparison process intermediate; intermediate compound which is used for  
 the preparation of pioglitazone)  
 IT 75-36-5, Acetyl chloride 501-53-1, Benzyl chloroformate 541-41-3,  
 Ethyl chloroformate 24424-99-5, Di-tert-butyl dicarbonate  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (comparison protecting agent; intermediate compound which is used for the  
 preparation of pioglitazone)  
 IT 3417-91-2, L-Tyrosine methyl ester hydrochloride  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (comparison starting material; intermediate compound which is used for  
 the preparation of pioglitazone)  
 IT 112529-15-4P, Pioglitazone hydrochloride  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (intermediate compound which is used for the preparation of pioglitazone)  
 IT 1080-06-4P, L-Tyrosine methyl ester 69955-04-0P, N-Benzyldiene-L-  
 tyrosine methyl ester 105355-26-8P, Pioglitazone 2-imine 144809-26-7P,  
 2-(5-Ethylpyridin-2-yl)ethyl methanesulfonate 674798-32-4P,  
 α-Bromo-4-[2-(5-ethylpyridin-2-yl)ethoxy]benzenepropanoic acid  
 795316-28-8P, N-Benzyldiene-O-[2-(5-ethylpyridin-2-yl)ethyl]-L-tyrosine  
 methyl ester  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic  
 preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (process intermediate; intermediate compound which is used for the  
 preparation

of pioglitazone)

IT 100-52-7, Benzaldehyde, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (protecting agent; intermediate compound which is used for the preparation  
 of  
 pioglitazone)

IT 60-18-4, L-Tyrosine, reactions 62-56-6, Thiourea, reactions 124-63-0,  
 Methanesulfonyl chloride 5223-06-3, 2-(5-Ethylpyridin-2-yl)ethanol  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; intermediate compound which is used for the preparation  
 of  
 pioglitazone)

IT 795316-22-2P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-DL-tyrosine  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic  
 preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (target intermediate; intermediate compound which is used for the  
 preparation  
 of pioglitazone)

IT 794591-56-3P, O-[2-(5-Ethylpyridin-2-yl)ethyl]-L-tyrosine 795316-27-7P,  
 O-[2-(5-Ethylpyridin-2-yl)ethyl]-D-tyrosine  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (target intermediate; intermediate compound which is used for the  
 preparation  
 of pioglitazone)



IT 111025-46-8P, Pioglitazone  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (target product; intermediate compound which is used for the preparation of  
 pioglitazone)


RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Leciva, A; WO 2002088120 A1 2002 CAPLUS
- (2) Meguro, K; US 4687777 A 1987 CAPLUS
- (3) Sumitomo Metal Ind Ltd; JP 08-325263 A 1996 CAPLUS
- (4) Sumitomo Metal Ind Ltd; [http://www4.ipdl.jpo.go.jp/Tokujitu/PAJdetail.ipdl?](http://www4.ipdl.jpo.go.jp/Tokujitu/PAJdetail.ipdl?N0000=60&N0120=01&N2001=2&N3001=H08-325263)  
 N0000=60&N0120=01&N2001=2&N3001=H08-325263 1996
- (5) Welfide Kk; JP 2000344748 A 2000 CAPLUS

RX(1) OF 80 ...A + B ==> C...





C

RX(1) RCT A 144809-26-7

STAGE(1)  
SOL 108-88-3 PhMe

STAGE(2)  
RGT D 584-08-7 K2CO3  
CAT 1643-19-2 Bu4N.Br

STAGE(3)  
RCT B 69955-04-0

STAGE(4)  
SOL 108-88-3 PhMe

STAGE(5)  
RGT D 584-08-7 K2CO3

STAGE(6)  
CAT 1643-19-2 Bu4N.Br


STAGE(7)  
RGT E 7647-01-0 HCl  
SOL 7732-18-5 Water

STAGE(8)  
RGT F 1310-73-2 NaOH  
SOL 7732-18-5 Water


STAGE(9)  
RGT E 7647-01-0 HCl  
SOL 7732-18-5 Water

PRO C 795316-22-2  
NTE last stage neutralization

RX(2) OF 80 ...J + K ==> B...




Updated Search



B

RX(2) RCT J 1080-06-4, K 100-52-7  
 PRO B 69955-04-0  
 SOL 75-09-2 CH<sub>2</sub>Cl<sub>2</sub>  
 CON overnight, room temperature

RX(3) OF 80 M + N ==> J...



J  
 YIELD 100%

RX(3) RCT M 60-18-4, N 67-56-1

STAGE(1)

SOL 67-56-1 MeOH  
 CON room temperature -> 0 deg C


STAGE(2)

RGT O 7719-09-7 SOCl<sub>2</sub>  
 CON SUBSTAGE(1) 20 minutes, 0 deg C  
 SUBSTAGE(2) 0 deg C -> room temperature  
 SUBSTAGE(3) room temperature -> reflux  
 SUBSTAGE(4) 4.5 hours, reflux

PRO J 1080-06-4

Updated Search

CCc1ccc(NC(=O)O)cc1
CC(=O)S(=O)(=O)Cl
 $\xrightarrow{(4)}$




```
STAGE(1)
  SOL  108-88-3 PhMe
  CON  room temperature

STAGE(2)
  RGT  R 121-44-8 Et3N
  CON  room temperature -> 0 deg C
```

PRO A 144809-26-7

Updated Search



T  
YIELD 41%

RX(5) RCT C 795316-22-2

STAGE(1)

SOL 7732-18-5 Water

STAGE(2)

RGT U 10035-10-6 HBr

SOL 7732-18-5 Water

STAGE(3)

RGT V 7632-00-0 NaNO2

SOL 7732-18-5 Water

STAGE(4)

SOL 75-09-2 CH2Cl2

STAGE(5)

RCT S 62-56-6

RGT W 127-09-3 AcONa

STAGE(6)

SOL 64-17-5 EtOH

STAGE(7)

RGT X 144-55-8 NaHCO3

SOL 7732-18-5 Water, 141-78-6 AcOEt

STAGE(8)

RGT E 7647-01-0 HCl

SOL 7732-18-5 Water

STAGE(9)

RGT F 1310-73-2 NaOH


SOL 7732-18-5 Water

PRO T 111025-46-8


NTE key step; last stage neutralization

RX(6) OF 80 ...J + AA ==> AB...

Updated Search




J



AA

(6) →



AB

YIELD 90%

RX(6) RCT J 1080-06-4

STAGE(1)

SOL 75-09-2 CH<sub>2</sub>Cl<sub>2</sub>

STAGE(2)

RGT R 121-44-8 Et<sub>3</sub>N

STAGE(3)

RCT AA 24424-99-5

SOL 75-09-2 CH<sub>2</sub>Cl<sub>2</sub>


STAGE(4)

SOL 7732-18-5 Water

PRO AB 4326-36-7

NTE last stage quench


RX(7) OF 80 ...A + AB ==> AC...



A


Updated Search





AB

(7)  $\longrightarrow$



AC

RX(7) RCT A 144809-26-7, AB 4326-36-7

STAGE(1)

SOL 108-88-3 PhMe

STAGE(2)


RGT D 584-08-7 K<sub>2</sub>CO<sub>3</sub>

STAGE(3)

SOL 67-56-1 MeOH, 108-88-3 PhMe

PRO AC 795316-23-3


RX(8) OF. 80 ...AC ==> AD...



AC

(8)  $\longrightarrow$

Updated Search



AD  
YIELD 42%

RX(8) RCT AC 795316-23-3

STAGE(1)

STAGE(2)

RGT AE 1310-58-3 KOH

SOL 7732-18-5 Water, 67-56-1 MeOH

STAGE(3)

SOL 67-56-1 MeOH

STAGE(4)

RGT O 7719-09-7 SOCl<sub>2</sub>


STAGE(5)

RGT X 144-55-8 NaHCO<sub>3</sub>

SOL 7732-18-5 Water


PRO AD 795316-25-5

RX(9) OF 80 ...AD ==> C...



AD

(9) →



C  
YIELD 63%

Updated Search

RX(9) RCT AD 795316-25-5

STAGE(1)

SOL 7732-18-5 Water, 67-56-1 MeOH

STAGE(2)

RGT AE 1310-58-3 KOH

STAGE(3)


RGT E 7647-01-0 HCl

SOL 7732-18-5 Water


PRO C 795316-22-2

NTE last stage neutralization

RX(10) OF 80 AF + AG ==> AH...




● HCl



AF

AG

(10) →



AH

YIELD 92%

RX(10) RCT AF 3417-91-2

STAGE(1)

STAGE(2)

RGT D 584-08-7 K2CO3

STAGE(3)

SOL 7732-18-5 Water, 67-64-1 Me2CO


Updated Search

STAGE(4)  
RCT AG 501-53-1


STAGE(5)  
SOL 141-78-6 AcOEt

PRO AH 13512-31-7

RX(11) OF 80 ...A + AH ==> AJ...




A



AH

(11) →



AJ

RX(11) RCT A 144809-26-7, AH 13512-31-7

STAGE(1)  
SOL 108-88-3 PhMe

STAGE(2)  
RGT D 584-08-7 K<sub>2</sub>CO<sub>3</sub>


STAGE(3)  
SOL 108-21-4 Acetic acid, 1-methylethyl ester

STAGE(4)  
CAT 1643-19-2 Bu<sub>4</sub>N.Br

PRO AJ 795316-26-6


Updated Search

RX(12) OF 80 ...AJ ==> C...



AJ

(12)



C  
YIELD 22%

RX(12) RCT AJ 795316-26-6

STAGE(1)

SOL 67-56-1 MeOH

STAGE(2)

RGT F 1310-73-2 NaOH

SOL 7732-18-5 Water

STAGE(3)

RGT E 7647-01-0 HCl

SOL 7732-18-5 Water

STAGE(4)


RGT F 1310-73-2 NaOH

SOL 7732-18-5 Water


PRO C 795316-22-2

NTE last stage neutralization

RX(13) OF 80 ...J + AL ==> AM...




J



AL

(13) →



AM

YIELD 85%

RX(13) RCT J 1080-06-4

STAGE(1)

STAGE(2)

RGT AN 497-19-8 Na2CO3

STAGE(3)


SOL 7732-18-5 Water, 75-09-2 CH2Cl2

STAGE(4)


RCT AL 75-36-5

PRO AM 2440-79-1


RX(14) OF 80 ...A + AM ==> C...



A



AM



C  
YIELD 14%

RX(14) RCT A 144809-26-7, AM 2440-79-1

STAGE(1)

STAGE(2)

RGT D 584-08-7 K<sub>2</sub>CO<sub>3</sub>  
CAT 1643-19-2 Bu<sub>4</sub>N.Br

STAGE(3)

SOL 108-88-3 PhMe

STAGE(4)


RGT F 1310-73-2 NaOH  
SOL 7732-18-5 Water


STAGE(5)

RGT E 7647-01-0 HCl  
SOL 7732-18-5 Water

PRO C 795316-22-2  
NTE last stage neutralization

RX(15) OF 80 ...J + AO ==> AP





AP  
YIELD 98%

RX(15) RCT J 1080-06-4

STAGE(1)

STAGE(2)

RGT D 584-08-7 K2CO3

STAGE(3)


SOL 7732-18-5 Water, 67-64-1 Me2CO

STAGE(4)


RCT AO 541-41-3

PRO AP 215596-38-6


RX(16) OF 80 A + AP ==> C



A



AP



C

RX(16) RCT A 144809-26-7, AP 215596-38-6

Updated Search



STAGE(1)

STAGE(2)

RGT D 584-08-7 K<sub>2</sub>CO<sub>3</sub>

STAGE(3)

SOL 108-21-4 Acetic acid, 1-methylethyl ester

STAGE(4)

SOL 7732-18-5 Water

STAGE(5)

RGT E 7647-01-0 HCl

SOL 7732-18-5 Water

PRO C 795316-22-2

NTE failed reaction